Edgewise Therapeutics/EWTX

$16.85

-1.11%
-
1D1W1MYTD1YMAX

About Edgewise Therapeutics

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for severe, rare neuromuscular and cardiac disorders. It has built its muscle-focused drug discovery platform. Its platform measures integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue. The Company’s lead candidate, EDG-5506, is an investigational orally administered small molecule designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies. EDG-5506 is advancing in multiple clinical trials in individuals with Duchenne, Becker and Limb Girdle 2i muscular dystrophies, and McArdles disease. The Company is also advancing EDG-7500, which is a sarcomere modulator for hypertrophic cardiomyopathy, into IND-enabling preclinical development.

Ticker

EWTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Kevin Koch

Employees

88

Headquarters

Boulder, United States

EWTX Metrics

BasicAdvanced
$1.61B
Market cap
-
P/E ratio
-$1.41
EPS
-
Beta
-
Dividend rate

What the Analysts think about EWTX

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
56.68% upside
High $32.00
Low $23.00
$16.85
Current price
$26.40
Average price target

EWTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-30.1M
17.12%
Profit margin
0%
-

EWTX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 3.54%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q1 24
Actual
-$0.36
-$0.34
-$0.41
-
Expected
-$0.36
-$0.40
-$0.40
-$0.39
Surprise
0%
-14.57%
3.54%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Edgewise Therapeutics stock

Buy or sell Edgewise Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing